Conflicting studies presented at the annual meeting of the American Society of Clinical Oncology suggest that â for now at least â itâs a toss-up.
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel â undetected by normal cells â through the bloodstream until activated by specific cancer proteins.
You read about first at KidneyCancer.org: In metastatic renal-cell cancer, the level of cytokines and angiogenic factors (CAF) identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.
Genetics researchers at Washington University in St. Louis, one of the worldâs leading centers for work on the human genome, were devastated. Dr. Lukas Wartman, a young, talented and beloved colleague, had the very cancer he had devoted his career to studying.
Actress talks about the life lessons she's teaching her daughters.
The bioartificial kidney will give ESRD patients new hope beyond the short-term solution of renal dialysis...
A human clinical trial under way at UPMC's Hillman Cancer Center in Shadyside will help determine whether a combination of approved drugs based on a new theory of cancer can "revolutionize cancer therapy."
Turner Syndrome is the #1 chromosomal abnormalities in females, and only 1% survive birth.
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.
Having completed enrollment of a 150-patient randomized Phase 2 study in advanced non-small cell lung cancer, Cerulean is beginning to capitalize on the breadth of the CRLX101 opportunity by expanding its development into additional tumor types with several studies conducted by leading investigators.